Scholarlink

Purpose of Review <p>Pediatric chronic hand eczema (P-CHE) is a debilitating condition that significantly impacts quality of life. Despite its rising prevalence, no P-CHE specific guidelines exist. Current management relies heavily on clinical experience, anecdotal evidence, and extrapolation from adult data. This review aims to identify gaps in P-CHE management and summarize current and emerging therapeutic options.</p> Recent Findings <p>Topical corticosteroids and non-pharmacological measures remain the cornerstone of P-CHE management. Topical calcineurin, topical Janus kinase (JAK) inhibitors, and phototherapy offer steroid-sparring alternatives. Although systemic treatments are often avoided due to safety concerns in children, they are essential for achieving adequate control and symptom management in severe or refractory cases. Alitretinoin, methotrexate, and cyclosporine are used cautiously off-label. Dupilumab, approved for pediatric atopic dermatitis, has shown promising efficacy and safety in P-CHE trials. Similarly, the use of oral JAK-inhibitors is at the forefront of emerging treatment options.</p> Summary <p>Effective P-CHE management requires a multifaceted, patient- and family-centered approach that balances efficacy, safety, and adherence. The literature reflects a critical gap in P-CHE specific data– especially in systemic therapies and non-atopic subtypes. Existing data is primarily derived from limited subgroup analyses within adult predominant trials, or from patients with atopic hand dermatitis enrolled within larger atopic dermatitis studies. Future research must address these gaps to inform guideline development and improve outcomes for affected children.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Review of Current and Emerging Treatments for Managing Pediatric Hand Eczema

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月15日

查看全文
  • Katie C.Y. Yeung,
  • Megan S. Lowe,
  • Sonja Molin

摘要

Purpose of Review

Pediatric chronic hand eczema (P-CHE) is a debilitating condition that significantly impacts quality of life. Despite its rising prevalence, no P-CHE specific guidelines exist. Current management relies heavily on clinical experience, anecdotal evidence, and extrapolation from adult data. This review aims to identify gaps in P-CHE management and summarize current and emerging therapeutic options.

Recent Findings

Topical corticosteroids and non-pharmacological measures remain the cornerstone of P-CHE management. Topical calcineurin, topical Janus kinase (JAK) inhibitors, and phototherapy offer steroid-sparring alternatives. Although systemic treatments are often avoided due to safety concerns in children, they are essential for achieving adequate control and symptom management in severe or refractory cases. Alitretinoin, methotrexate, and cyclosporine are used cautiously off-label. Dupilumab, approved for pediatric atopic dermatitis, has shown promising efficacy and safety in P-CHE trials. Similarly, the use of oral JAK-inhibitors is at the forefront of emerging treatment options.

Summary

Effective P-CHE management requires a multifaceted, patient- and family-centered approach that balances efficacy, safety, and adherence. The literature reflects a critical gap in P-CHE specific data– especially in systemic therapies and non-atopic subtypes. Existing data is primarily derived from limited subgroup analyses within adult predominant trials, or from patients with atopic hand dermatitis enrolled within larger atopic dermatitis studies. Future research must address these gaps to inform guideline development and improve outcomes for affected children.